Sign up to save your podcasts
Or
Share Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?
Normalization of PET-CT is a strong predictor for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM)
Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
View all episodes
By American Society of Clinical Oncology (ASCO)
3.8
3939 ratings
Normalization of PET-CT is a strong predictor for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM)
Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
More shows like Journal of Clinical Oncology (JCO) Podcast
View all
NPR News Now
14,364 Listeners
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
498 Listeners
ASCO Daily News
58 Listeners
The Daily
112,758 Listeners
ASCO Guidelines
44 Listeners
ASCO Education
32 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Run the List
253 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
41 Listeners
The Headlines
613 Listeners